Meeting unmet medical needs has its price. Consider the 21st Century Cures legislation. The sweeping Congressional bill, which is designed to jumpstart medical innovation, has a provision that would allow the FDA to grant an extra six months of exclusive marketing rights to a company if an existing drug is approved to treat a rare disease. Jerry Avorn, professor of medicine at Brigham and Women's Hospital, is quoted.